LAMEA Atopic Dermatitis Drugs Market

LAMEA Atopic Dermatitis Drugs Market Size, Share & Industry Trends Analysis Report By Route of Administration, By Class (Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors), By Country and Growth Forecast, 2022 - 2028

Report Id: KBV-12219 Publication Date: November-2022 Number of Pages: 82
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Atopic Dermatitis Drugs Market, by Route of Administration
1.4.2 LAMEA Atopic Dermatitis Drugs Market, by Class
1.4.3 LAMEA Atopic Dermatitis Drugs Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Acquisition and Mergers
3.2.2 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers : 2018, Sep – 2022, Oct) Leading Players

Chapter 4. LAMEA Atopic Dermatitis Drugs Market by Route of Administration
4.1 LAMEA Injectable Market by Country
4.2 LAMEA Oral Market by Country
4.3 LAMEA Topical Market by Country

Chapter 5. LAMEA Atopic Dermatitis Drugs Market by Class
5.1 LAMEA Biologics Market by Country
5.2 LAMEA Calcineurin Inhibitors Market by Country
5.3 LAMEA Corticosteroids Market by Country
5.4 LAMEA PDE4 Inhibitors Market by Country
5.5 LAMEA Others Market by Country

Chapter 6. LAMEA Atopic Dermatitis Drugs Market by Country
6.1 Brazil Atopic Dermatitis Drugs Market
6.1.1 Brazil Atopic Dermatitis Drugs Market by Route of Administration
6.1.2 Brazil Atopic Dermatitis Drugs Market by Class
6.2 Argentina Atopic Dermatitis Drugs Market
6.2.1 Argentina Atopic Dermatitis Drugs Market by Route of Administration
6.2.2 Argentina Atopic Dermatitis Drugs Market by Class
6.3 UAE Atopic Dermatitis Drugs Market
6.3.1 UAE Atopic Dermatitis Drugs Market by Route of Administration
6.3.2 UAE Atopic Dermatitis Drugs Market by Class
6.4 Saudi Arabia Atopic Dermatitis Drugs Market
6.4.1 Saudi Arabia Atopic Dermatitis Drugs Market by Route of Administration
6.4.2 Saudi Arabia Atopic Dermatitis Drugs Market by Class
6.5 South Africa Atopic Dermatitis Drugs Market
6.5.1 South Africa Atopic Dermatitis Drugs Market by Route of Administration
6.5.2 South Africa Atopic Dermatitis Drugs Market by Class
6.6 Nigeria Atopic Dermatitis Drugs Market
6.6.1 Nigeria Atopic Dermatitis Drugs Market by Route of Administration
6.6.2 Nigeria Atopic Dermatitis Drugs Market by Class
6.7 Rest of LAMEA Atopic Dermatitis Drugs Market
6.7.1 Rest of LAMEA Atopic Dermatitis Drugs Market by Route of Administration
6.7.2 Rest of LAMEA Atopic Dermatitis Drugs Market by Class

Chapter 7. Company Profiles
7.1 Pfizer, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional & Segmental Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Approvals and Trials:
7.1.5.2 Acquisition and Mergers:
7.2 Novartis AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.3 Sanofi S.A.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals and Trials:
7.3.5.2 Acquisition and Mergers:
7.4 LEO Pharma A/S
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Approvals and Trials:
7.4.5.2 Acquisition and Mergers:
7.5 Incyte Corporation
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Research & Development Expenses
7.5.4 Recent strategies and developments:
7.5.4.1 Approvals and Trials:
7.5.4.2 Acquisition and Mergers:
7.6 AbbVie, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Approvals and Trials:
7.6.5.2 Acquisition and Mergers:
7.7 Regeneron Pharmaceuticals, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expense
7.8 Eli Lilly And Company
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.9 Otsuka Pharmaceutical Co., Ltd.
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Approvals and Trials:
7.9.2.2 Acquisition and Mergers:
7.10. Galderma S.A.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Acquisition and Mergers:
HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings


  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo